Methods for treatment of insulin-like growth factor-1 deficiency
The present invention provides methods and compositions for increasing the growth rates, alleviating the symptoms, or improving the metabolism of human patients having an endocrine disorder characterized by partial endogenous growth hormone activity or signaling. The invention provides a method comprising administering to a patient suffering from an endocrine disorder characterized by partial endogenous growth hormone activity or signaling an amount of insulin-like growth factor-1 (IGF-1) effective to improve metabolism in the patient, where the patient receives IGF-1 in a single daily administration. The invention also provides a method comprising administering to a patient suffering from an endocrine disorder characterized by partial endogenous growth hormone activity or signaling an amount of insulin-like growth factor-1 (IGF-1) and an amount of growth hormone (GH) that in combination are effective to improve growth or metabolism in the patient, where the patient receives IGF-1 in a single daily administration and receives GH in a single daily administration, and where the single IGF-1 administration and the single GH administration are administered to the patient substantially contemporaneously each day.
1. A method for treating a human pediatric subject having primary insulin-like growth factor-1 deficiency (IGFD) comprising;
administering to a human pediatric subject suffering from a growth disorder characterized by primary IGFD and partial endogenous growth hormone signaling a combination of an amount of insulin-like growth factor-1 (IGF-1) and an amount of growth hormone (GH) effective to promote growth in the subject, wherein the subject is further characterized as follows:
the subject, at the time of treatment or prior to initial treatment with IGF-1, has or had a height at least about 2.0 standard deviations (SD) below a normal mean for a subject of the same age and gender, and
the subject has or had a blood level of IGF-1 below, but not more than about 2 SD below, normal mean levels for a subject of the same age and gender,
wherein the subject receives each of IGF-1 and GH in a single administration per day, and wherein the single administration of IGF-1 and the single administration of GH are administered to the patient substantially contemporaneously each day.
2. The method of claim 1 , wherein IGF-1 is administered in a dose of about 25 to 250 μg/kg/day and GH is administered in a dose of about 0.05 to 0.5 mg/kg/week.
3. The method of claim 1 , wherein IGF-1 is administered in a dose of about 20 to 240 μg/kg/day.
4. The method of claim 1 , wherein the single administration of GH and the single administration of IGF-1 are each administered to the patient by subcutaneous injection.
5. The method of claim 1 , wherein the subject is further characterized as having a blood level of growth hormone-binding protein (GHBP) which is at least normal for a subject of the same age and gender.
6. The method of claim 1 , wherein the subject does not have partial growth hormone insensitivity syndrome.
7. The method of claim 1 , wherein the subject receives the single administration of IGF-1 and the single administration of GH within about 2 hours of awakening from sleep each day.
8. The method of claim 1 , wherein the subject receives the single administration of IGF-1 with a meal or snack.
9. The method of claim 1 , wherein the subject does not receive treatment with insulin-like growth factor binding protein-3 (IGFBP-3) concomitantly with the IGF-1 therapy of the method.
10. The method of claim 1 , wherein the GH and the IGF-1 are in the form of separate solutions that are administered by separate injections.
11. The method of claim 10 , wherein IGF-1 is administered in a dose of about 25 to 250 μg/kg/day and GH is administered in a dose of about 0.05 to 0.5 mg/kg/week.
12. The method of claim 10 , wherein IGF-1 is administered in a dose of about 20 to 240 μg/kg/day.
13. The method of claim 10 , wherein the single administration of GH and the single administration of IGF-1 are each administered to the patient by subcutaneous injection.
14. The method of claim 10 , wherein the subject is further characterized as having a blood level of growth hormone binding protein (GHBP) which is at least normal for a subject of the same age and gender.
15. The method of claim 10 , wherein the subject does not have partial growth hormone insensitivity syndrome.
16. The method of claim 10 , wherein the subject receives the single administration of IGF-1 and the single administration of GH within about 2 hours of awakening from sleep each day.
17. The method of claim 10 , wherein the subject receives the single administration of IGF-1 with a meal or snack.
18. The method of claim 10 , wherein the subject does not receive treatment with insulin-like growth factor binding protein-3 (IGFBP-3) concomitantly with the IGF-1 therapy of the method.